On August 29, Illumina fell 5.07% in regular trading, trading at $216.245/share, with turnover of $234 million. The decline was triggered by disclosure of significant insider selling activity that weighed on investor confidence.
The company recently disclosed 28 insider transactions, with Director Keith A. Meister conducting concentrated selling of approximately 133,300 shares between August 19 and 21, totaling over $27 million at average prices ranging from $202 to $211 per share. The large-scale reduction by a board member placed notable pressure on market sentiment.
Meanwhile, the Life Sciences Tools & Services sector exhibited broad-based weakness, amplifying selling pressure through sector linkage effects. Among sector peers, Tempus AI declined 9.36%, Thermo Fisher Scientific fell 1.59%, Agilent dropped 1.38%, and IQVIA slipped 0.1%, while Danaher edged up 0.33%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments